We have identified several well-known mutations that affect anti-cancer drug response, such as those in TP53, BRAF, NRAS, KRAS. In this analysis, the cellular response to Nutlin3, is found to be related with MDM2 expression and TP53 mutation. This evidence concerns the gene BRAF and cancer.